Last Updated on October 15, 2024 by The Health Master
Amylyx Pharma said the US Food and Drug Administration (USFDA) approved its drug for slowing the progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death, sending shares of the company up nearly 14 percent in extended trading.
The company added healthcare professionals can soon write prescriptions for the drug, to be sold under the brand name Relyvrio, while it is working on the launch.
“We know people living with ALS have no time to wait, and, for this reason, Amylyx is prepared to move quickly with commercialization in the US,” Josh Cohen and Justin Klee, Co-Chief Executive Officers, said in a statement.
Amylyx’s drug is a combination of generic compounds sodium phenylbutyrate and taurursodiol that work together to prevent nerve cells in the brain and spinal cord from dying prematurely.
Amylyx’s case for approval was built on a recent analysis of clinical trial data that it said showed the drug slows the progression of the disease and extends life expectancy by nearly 10 months.
USFDA staff had expressed concerns earlier this month that the additional analysis came from the same small mid-stage trial as the initial data and could not be considered as confirmation of the drug’s benefits.
The USFDA’s decision, a rare reversal, follows an approval recommendation from an outside panel of advisers. The agency reconvened the panel in September to look at the new data analyses after it had previously recommended against approving the drug in March.
Relyvrio is the third ALS drug to be approved by the USFDA, following Japanese firm Mitsubishi Tanabe’s Radicava and the generic drug riluzole.
USFDA approves Mirabegron extended-release tablets
USFDA gives nod for this generic non-steroidal anti-inflammatory drug
USFDA approves Intravenous therapy for hearing loss
USFDA approves Terlipressin for injection to treat Kidney function
USFDA gives tentative approval for Sugammadex Injection
USFDA gives approval for Lenalidomide capsules
FDA to Doctors, Hospitals: Report adverse drug reactions
USFDA approves Mirabegron extended-release tablets
State FDAs of these states to be strengthened soon
Drug recall: Acyclovir Sodium Injection recalled due to this reason
FDA J&K suspended licenses of Medicals Stores & Pharma Dealers
J & J appeals to Maharashtra FDA minister to revoke cancellation of license
Changing the Regulations for Class A Medical Devices and its Impact
Govt plan to ban Codeine based cough syrups opposed by Pharma companies
Pharmacists – The Doctors behind the screens
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
